Determining the commercial potential of the first-in-class small molecule allosteric modulators at the human gastric inhibitory polypeptide receptor
Lead Research Organisation:
University of Cambridge
Department Name: Pharmacology
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Graham Ladds (Principal Investigator) |
| Description | This award was a small fund to commission an expert in the pharmaceutical industry to review our new novel small molecule modulators of the gastric inhibitory polypeptide receptor. The report suggested that the compounds had potential as novel anti-diabetic drugs. We then submitted a BBSRC FoF application to develop these compounds further but it was unsuccessful. We have now however engaged a pharmaceutical company to aid in their development. |
| Exploitation Route | As stated we have now entered into a partnership with a global pharmaceutical company to develop these compounds further. |
| Sectors | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Description | We have now signed a contract with Takeda Pharmaceuticals to study GIPR and molecules associated with GIPR. |
| First Year Of Impact | 2021 |
| Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |